(Q51161068)

31 March 2018

title

De-escalation from natalizumab in multiple sclerosis: recurrence of disease activity despite switching to glatiramer acetate. (English)

1 reference

31 March 2018

0 references

2

Lisa Ann Gerdes

1 reference

31 March 2018

author name string

Joachim Havla

1

1 reference

31 March 2018

Ingrid Meinl

3

1 reference

31 March 2018

Markus Krumbholz

4

1 reference

31 March 2018

Hans Faber

5

1 reference

31 March 2018

Frank Weber

6

1 reference

31 March 2018

Hannah Luise Pellkofer

7

1 reference

31 March 2018

Reinhard Hohlfeld

8

1 reference

31 March 2018

Tania Kümpfel

9

1 reference

31 March 2018

publication date

23 March 2011

1 reference

31 March 2018

published in

Journal of Neurology

1 reference

31 March 2018

volume

258

1 reference

31 March 2018

issue

9

1 reference

31 March 2018

page(s)

1665-1669

1 reference

31 March 2018

https://scigraph.springernature.com/pub.10.1007/s00415-011-5996-y

exact match

0 references

cites work

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-5996-Y

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-5996-Y

Progressive multifocal leukoencephalopathy in a patient treated with natalizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-5996-Y

Progressive multifocal leukoencephalopathy after natalizumab monotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-5996-Y

Immune surveillance in multiple sclerosis patients treated with natalizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-5996-Y

Natalizumab drug holiday in multiple sclerosis: poorly tolerated

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-5996-Y

GLANCE: results of a phase 2, randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-5996-Y

Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-011-5996-Y

Immune reconstitution inflammatory syndrome after withdrawal of natalizumab?

21 January 2018

1 reference

12 December 2020

Immune reconstitution inflammatory syndrome in patients with multiple sclerosis following cessation of natalizumab therapy

1 reference

12 December 2020

Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients

1 reference

12 December 2020

Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis

1 reference

12 December 2020

10.1007/S00415-011-5996-Y

Identifiers

DOI

1 reference

31 March 2018

1 reference

31 March 2018